SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

September 30, 2002

Study Completion Date

January 31, 2006

Conditions
Prostate Cancer
Interventions
DRUG

dexamethasone

DRUG

semaxanib

Trial Locations (18)

27705

Veterans Affairs Medical Center - Durham, Durham

46617

Michiana Hematology/Oncology P.C., South Bend

49085

Oncology Care Associates, P.L.L.C., Saint Joseph

60068

Division of Hematology/Oncology, Park Ridge

60153

Loyola University Medical Center, Maywood

60201

Evanston Northwestern Health Care, Evanston

60426

Ingalls Memorial Hospital, Harvey

60525

LaGrange Memorial Hospital, LaGrange

60612

University of Illinois at Chicago, Chicago

60640

Louis A. Weiss Memorial Hospital, Chicago

61602

Oncology/Hematology Associates of Central Illinois, P.C., Peoria

62526

Cancer Care Specialists of Central Illinois, S.C., Decatur

62701

Central Illinois Hematology Oncology Center, Springfield

91105

City of Hope Medical Group, Pasadena

91010-3000

Cancer Center and Beckman Research Institute, City of Hope, Duarte

90033-0804

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

60637-1470

University of Chicago Cancer Research Center, Chicago

46885-5099

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER

NCT00006002 - SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy | Biotech Hunter | Biotech Hunter